Drug Trial Radar · NCT05803941
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Aug 14, 2023
Primary completion
Jul 20, 2033
Study completion Jul 21, 2033
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other AAA617 causally related serious adverse event(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical trials.
Conditions
- Prostate Cancer
Interventions
AAA617Drug
Long-term follow-up (LTFU) safety study of adult participants with prostate cancer that have received at least one dose of AAA617 from parent interventional Novartis sponsored clinical trials.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and percentage of participants with selected Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: every visit up to 10 years after 1st dose of AAA617 received in parent treatment study
Locations
54 sites in 11 countries. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Scottsdale, Arizona · Recruiting
St. Joseph Hospital
Orange, California · Recruiting
Providence Saint Johns Health Ctr
Santa Monica, California · Recruiting
University of Colorado
Aurora, Colorado · Recruiting
Hartford Hospital
Hartford, Connecticut · Recruiting
VA Medical Center
Washington D.C., District of Columbia · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
University Cancer and Blood Center LLC
Athens, Georgia · Recruiting
Parkview Research Center
Fort Wayne, Indiana · Recruiting
Tulane Cancer Center
New Orleans, Louisiana · Recruiting
Ochsner Clinic Foundation
New Orleans, Louisiana · Recruiting
Corewell Health William Beaum Hosp
Royal Oak, Michigan · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
University of Mississippi Med Ctr
Jackson, Mississippi · Recruiting
Wash U School of Medicine
St Louis, Missouri · Recruiting
Urology Cancer Center PC
Omaha, Nebraska · Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Cleveland Clinic Foundation
Cleveland, Ohio · Recruiting
Univ of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
Univ of Texas Southwest Med Center
Dallas, Texas · Recruiting
UT Health Science Center
Houston, Texas · Recruiting
Onco Hemato Asso of SW Virginia
Roanoke, Virginia · Recruiting
Novartis Investigative Site
Linz, Austria · Recruiting
Novartis Investigative Site
Vienna, Austria · Recruiting
Novartis Investigative Site
Ghent, Belgium · Recruiting
Novartis Investigative Site
Montreal, Quebec, Canada · Recruiting
Novartis Investigative Site
Olomouc, Czechia · Recruiting
Novartis Investigative Site
Prague, Czechia · Recruiting
Novartis Investigative Site
Lyon, France · Recruiting
Novartis Investigative Site
Essen, Germany · Recruiting
Novartis Investigative Site
München, Germany · Recruiting
Novartis Investigative Site
Rostock, Germany · Recruiting
Novartis Investigative Site
Nijmegen, Gelderland, Netherlands · Recruiting
Novartis Investigative Site
Maastricht, Limburg, Netherlands · Recruiting
Novartis Investigative Site
Delft, South Holland, Netherlands · Recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Barcelona, Spain · Recruiting
Novartis Investigative Site
Madrid, Spain · Recruiting
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.